Open access · CC-BY
via OpenAlex
Inflammaging and Midlife Women: Translating Geroscience into Clinical Practice
Journal of Mid-life Health · 2026
Mitochondrial dysfunction
Cellular senescence
Altered intercellular communication
Chronic inflammation
Exercise
Human
Abstract
Aging is no longer viewed merely as the passive passage of time. Instead, it is increasingly understood as an active biological process driven by complex interactions between immunity, metabolism, hormones, and environment. One of the most compelling concepts to emerge from this paradigm shift is “inflammaging(definition)” – a state of chronic, low-grade inflammation that accompanies aging and underlies many age-related diseases. Coined by Claudio Franceschi over two decades ago, inflammaging has now become a cornerstone of geroscience, linking immune dysregulation with longevity and disease vulnerability.[1] For women, midlife and menopause represent a critical biological modulation point in the inflammaging trajectory. The menopausal transition is not simply a reproductive milestone; it is a systemic event with far-reaching immunological, metabolic, cardiovascular, skeletal, and neurocognitive implications.[2] As life expectancy for Indian women has risen dramatically – from approximately 35 years before independence to over 70 years today – the relevance of inflammaging in midlife women has never been greater. This editorial argues that adopting the inflammaging framework moves us beyond treating menopausal symptoms in isolation and toward a unified strategy for preventing the chronic diseases of aging. INFLAMMAGING MATTERS IN MIDLIFE The risk of health problems from all causes increases rapidly after the age of 50 years, doubling approximately every 8 years. This acceleration coincides with immunosenescence – a gradual decline in immune competence – paradoxically accompanied by heightened inflammatory signaling. Elevated circulating levels of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP) are consistently associated with frailty, sarcopenia, insulin resistance, atherosclerosis, osteoporosis, cognitive decline, and malignancy. In women, the menopausal decline in estrogen acts as a powerful biological amplifier of this inflammatory milieu. Estrogen is not merely a reproductive hormone; it is a key immunomodulator with anti-inflammatory, antioxidant, and mitochondrial-protective actions. Its withdrawal unmasks inflammatory pathways that were previously restrained, accelerating biological aging. Menopause acts as an accelerator of inflammaging. The loss of 17β-estradiol during menopause leads to disinhibition of nuclear factor-κB signaling, resulting in increased transcription of inflammatory cytokines. Simultaneously, estrogen deficiency contributes to mitochondrial dysfunction(definition), increased reactive oxygen species generation, and cellular senescence(definition).[3,4] Senescent cells accumulate in aging tissues and secrete a pro-inflammatory senescence-associated secretory phenotype, perpetuating local and systemic inflammation.[5] Clinically, this biology manifests as increased visceral adiposity, insulin resistance, dyslipidemia, endothelial dysfunction, bone loss, and neuroinflammation – hallmarks of postmenopausal morbidity. Importantly, inflammaging provides a unifying mechanism linking menopause to chronic diseases traditionally considered unrelated.[6] The key mechanistic pathways underlying this process are summarized in Table 1.Table 1: Menopause as an accelerator of inflammaging: Pathophysiological trigger[ 6 ]There are gender differences in immune aging. Sex-based differences in immune aging are increasingly recognized. Women generally mount stronger immune responses than men during reproductive years, conferring advantages in infection control but also higher susceptibility to autoimmune diseases. After menopause, however, the abrupt decline in estrogen leads to a steeper rise in inflammatory biomarkers compared to the more gradual inflammaging observed in aging men with declining testosterone levels. These differences have implications for disease patterns, vaccine responses, and therapeutic strategies. Understanding inflammaging through a gender-sensitive lens is therefore essential for precision midlife medicine. In India, this may be viewed as “A Silent Epidemic.” India faces a unique convergence of challenges. Rapid urbanization, dietary transitions, physical inactivity, psychosocial stress, and increasing obesity have created a fertile ground for chronic low-grade inflammation – even before menopause. High-glycemic diets, trans fats, excess refined carbohydrates, and sugary beverages contribute to insulin spikes and adipose-driven cytokine release, fuelling inflammaging at younger ages. For Indian women, who often prioritize family health over their own and may have limited access to preventive care, menopause frequently coincides with undiagnosed cardiometabolic risk. Inflammaging thus becomes a silent epidemic – clinically invisible until overt disease emerges. An important question is whether inflammaging can be modified? Emerging evidence suggests that aspects of inflammaging may be modifiable. Unlike chronological aging, biological aging is responsive to targeted interventions – many of which are accessible, cost-effective, and culturally adaptable. It is crucial to note that the anti-inflammatory benefits of menopausal hormone therapy (MHT) are most pronounced when initiated during the perimenopause or early postmenopause – the “window of opportunity” – before atherogenesis and inflammatory pathways are fully established. Late initiation may not reverse established inflammaging and could potentially trigger adverse events. MHT, when initiated within the “window of opportunity,” has been shown to modulate the inflammatory markers such as IL-6, TNF-α, and CRP, improve lipid profiles, and enhance vascular function. Beyond symptom relief, MHT may favorably influence immune aging in appropriately selected women.[7] Lifestyle interventions play an important role in reducing inflammatory response. Regular physical activity – combining aerobic exercise with resistance training – reduces visceral fat, enhances anti-inflammatory
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.4103/jmh.jmh_77_26
- Canonical
- link ↗
- Fetched
- 2026-10-06 MST
Cite this
APA
Munshi, A., & Garg, R. (2026). Inflammaging and Midlife Women: Translating Geroscience into Clinical Practice. <em>Journal of Mid-life Health</em>. https://doi.org/10.4103/jmh.jmh_77_26
Vancouver
Munshi A, Garg R. Inflammaging and Midlife Women: Translating Geroscience into Clinical Practice. Journal of Mid-life Health. 2026. doi:10.4103/jmh.jmh_77_26.
BibTeX
@article{atul2026Inflam,
title = {Inflammaging and Midlife Women: Translating Geroscience into Clinical Practice},
author = {Atul Munshi and Ruchika Garg},
journal = {Journal of Mid-life Health},
year = {2026},
doi = {10.4103/jmh.jmh_77_26},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
High Blood Pressure & Cardiovascular Prevention 2025
Open access · CC-BY
Inflammaging and Cardiovascular Risk in Old Women
African Journal of Biomedical Research 2026
Open access · CC-BY
Inflammaging in Cardiovascular Disease: Emerging Mechanisms and Therapeutic Perspectives
Frontiers in Pharmacology 2026
Open access · CC-BY
Chronic inflammation as a driving factor for sarcopenia: an update on pathophysiology and future therapeutic targets
Current Genetics 2017
Open access · CC-BY
Starvation signals in yeast are integrated to coordinate metabolic reprogramming and stress response to ensure longevity
2026
Open access · OA
Senolytic therapy in Alzheimer’s disease: clinical evidence and biomarkers
Immunity & Ageing 2013
Open access · CC-BY